Aflibercept biosimilar (Mabwell Bioscience)

The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints GenSci148 项目展示了从一次性突变预测向在真实药物研发约束下进行迭代式蛋白质工程的转变SHANGHAI 上海, ，Aug. 20, 2026 2026年8月20日/PRNewswire/ -- /美通社/ --Shanghai Matwings Technology Co., Ltd. ('Matwings') 上海马翼科技有限公司（“马翼”）today announced that 今日宣布GenSci148 Injection GenSci148 注射液, an investigational ophthalmic biologic developed by ，一种由……开发的在研眼科生物制剂Changchun GeneScience Pharmaceutical Co., Ltd. ('GenSci') 长春金赛药业股份有限公司（“GenSci”）, has received clinical trial clearance in China for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). ，已在中国获得针对新生血管性年龄相关性黄斑变性（nAMD）、糖尿病性黄斑水肿（DME）和视网膜静脉阻塞（RVO）的临床试验批准。Matwings supported the GenSci148 program through four iterative AI–wet lab cycles covering 222 protein variants. Rather than applying AI as a one-time mutation-prediction tool, the teams repeatedly used experimental results to redesign both molecules and optimization objectives. The program progressed from improving biological activity to balancing potency, stability, expression, formulation and other development-relevant properties—illustrating a shift from predicting mutations to engineering therapeutic proteins under real drug-development constraints.. Matwings 通过四轮迭代的人工智能与湿实验循环，支持了 GenSci148 项目，涵盖了 222 种蛋白质变体。团队并未将人工智能仅作为一次性的突变预测工具，而是反复利用实验结果重新设计分子并优化目标。该项目从最初提高生物活性，逐步发展到平衡效价、稳定性、表达量、制剂以及其他与开发相关的属性，体现了从单纯预测突变向在真实药物开发约束条件下工程化治疗性蛋白质的转变。Four AI–Wet Lab Cycles, 222 Variants 四个AI-湿实验循环，222个变体Matwings and GenSci implemented a closed-loop workflow combining Matwings 和 GenSci 实施了结合闭环工作流程AI-guided molecular design, wet-lab testing, experimental feedback and redesign AI引导的分子设计、湿实验测试、实验反馈与重新设计. 。Across 横向four iterative cycles 四个迭代周期, the teams evaluated ，各团队评估了222 protein variants 222种蛋白质变体. The first two rounds assessed 92 and 30 variants, respectively, with an initial focus on biological activity. The next two rounds evaluated 50 variants each, expanding the optimization objectives to include high-concentration formulation viscosity and broader developability requirements. 前两轮分别评估了92种和30种变体，初步聚焦于生物活性。接下来的两轮各评估了50种变体，将优化目标扩展至包括高浓度制剂粘度以及更广泛的可开发性要求。Experimental results from each round were incorporated into subsequent design cycles, allowing not only the molecular designs but also the optimization objectives to evolve as evidence accumulated. 每一轮的实验结果都被纳入后续的设计循环中，使得随着证据的积累，不仅分子设计得以演进，优化目标也随之调整。The campaign therefore progressed from: 因此，活动进展如下：activity optimization → broader developability optimization → multi-objective molecular engineering 活性优化 → 更广泛的可开发性优化 → 多目标分子工程Across the optimization campaign, experimentally tested variants demonstrated improvements or favorable performance across six development-relevant properties: 在整个优化活动中，经过实验测试的变体在六个与开发相关的属性上均表现出改进或良好的性能：Development Parameter 开发参数Observed Result 观测结果VEGF-A binding affinity VEGF-A结合亲和力Up to approximately 最高约10-fold improvement 10倍提升VEGF-A/C/D functional VEGF-A/C/D 功能blockade 封锁Up to approximately 最高约3-fold improvement 三倍提升Nonclinical in vivo activity 非临床体内活性Inhibitory activity observed 观察到抑制活性84 days after dosing in the 给药后第84天evaluated retinal model 评估的视网膜模型Thermal stability 热稳定性Tm increased by up to approximately 4.5°C Tm 升高了约 4.5°CProtein expression 蛋白质表达Increased by up to approximately 增加至多约27.6% 27.6%High-concentration formulation 高浓度制剂viscosity 粘度Reduced by approximately 减少了大约13 cP 13 厘泊Together, these results reflect optimization across three increasingly demanding dimensions of therapeutic protein development: biological performance, molecular developability and formulation-relevant properties. 这些结果共同反映了在治疗性蛋白质开发的三个日益严苛的维度上的优化：生物性能、分子可开发性以及与制剂相关的特性。In the nonclinical retinal model evaluated during the program, the optimized molecule maintained inhibitory activity 84 days after dosing. Under the specific experimental conditions tested, it also showed greater inhibition than aflibercept and faricimab. 在该项目评估的非临床视网膜模型中，优化后的分子在给药后84天仍保持抑制活性。在测试的特定实验条件下，其抑制作用也强于阿柏西普和法瑞西单抗。These findings are preclinical and do not establish comparative clinical efficacy or safety. 这些发现属于临床前研究结果，并未确立比较性的临床疗效或安全性。Beyond Mutation Prediction: Engineering Proteins Under Real Drug-Development Constraints 超越突变预测：在真实药物开发约束下进行蛋白质工程Therapeutic protein engineering requires balancing biological activity with stability, expression, formulation and other development constraints. In the GenSci148 program, experimental results continuously informed subsequent AI-guided designs, enabling the optimization process to move beyond a single fixed objective.. 治疗性蛋白质工程需要在生物活性与稳定性、表达、制剂以及其他开发约束之间取得平衡。在 GenSci148 项目中，实验结果持续为后续的人工智能引导设计提供依据，使优化过程能够超越单一固定目标。Some experimentally validated mutations were located 一些经实验验证的突变位于away from the conventional target-binding interface 远离传统的靶标结合界面, illustrating how AI-guided exploration can identify productive regions of sequence space beyond interface-focused design. ，展示了人工智能引导的探索如何识别序列空间中超越界面聚焦设计的高效区域。The program also illustrates a broader progression in protein AI validation: 该计划还展示了蛋白质人工智能验证方面更广泛的进展：computational benchmarking → experimental validation → repeated integration within a real drug-development workflow 计算基准测试 → 实验验证 → 在真实药物研发流程中的反复整合GenSci148 represents the third stage of this progression, with AI-guided design and experimental evidence repeatedly linked across successive engineering cycles. GenSci148 代表了这一进程的第三阶段，其中人工智能引导的设计与实验证据在连续的工程周期中反复相互印证。The Venus Protein AI Stack 维纳斯蛋白质人工智能栈Matwings' 马特温斯Venus 金星protein AI stack has evolved from sequence-centered modeling toward systems integrating three-dimensional structure, evolutionary information and task-specific capabilities. Importantly, the AI-guided engineering work supporting GenSci148 was conducted using 蛋白质人工智能技术栈已从以序列为中心的建模，演变为整合三维结构、进化信息和任务特定能力的系统。重要的是，支持 GenSci148 的 AI 引导工程工作是在以下基础上开展的：Venus 1.0 金星 1.0, while Venus has since advanced to ，而金星此后已推进至Venus 3.0, represented by VenusREM 由 VenusREM 代表的 Venus 3.0, which integrates protein sequence, three-dimensional structure and evolutionary information for mutation-effect prediction. ，该方法整合蛋白质序列、三维结构和进化信息，用于突变效应预测。Rather than relying on a single model, different components are applied to different protein R&D and engineering tasks within the broader closed-loop workflow. 在更广泛的闭环工作流程中，不同的组件被应用于不同的蛋白质研发和工程任务，而不是依赖于单一模型。Generation 生成Representative Model(s) 代表性模型Information Integrated 信息集成Primary Role 主要角色Venus 1.0 金星 1.0Venus 1.0 金星 1.0Protein sequence 蛋白质序列Sequence- 序列-centered 居中modeling 建模Venus 2.0 金星 2.0Venus-ProSST 金星-ProSSTSequence + 3D structure 序列 + 三维结构Structure-aware 结构感知modeling 建模Venus 3.0 金星 3.0VenusREM 金星REMSequence + 3D structure + 序列 + 三维结构 +evolutionary information 进化信息Mutation-effect 突变效应prediction 预测Task-Specific 任务特定Models 模型Venus-FSFP, Venus-Maxwell, Venus-Mine, Venus-RXN, Venus- 金星-FSFP，金星-麦克斯韦，金星-Mine，金星-RXN，金星-Fold 折叠Task-dependent 任务依赖型Protein R&D and 蛋白质研发及engineering 工程Certain models within the broader Venus portfolio are in development or planned stages. 维纳斯产品组合中的某些型号正处于开发或规划阶段。Together, these models form a specialist AI stack that can be combined with experimental data and iterative design across different stages of protein engineering. 这些模型共同构成了一个专业化的AI技术栈，能够与实验数据及迭代设计相结合，应用于蛋白质工程的不同阶段。From External Validation to Therapeutic Creation 从外部验证到治疗性创造The GenSci148 collaboration provides external validation of Matwings' protein-engineering capabilities in a real therapeutic development program. GenSci148 合作项目在真实的药物研发项目中，对外部验证了 Matwings 的蛋白质工程能力。In March 2026, Matwings established 2026年3月，Matwings成立Shanghai Biowings Therapeutics Co., Ltd. ('Biowings Therapeutics') 上海百奥维生制药有限公司（“百奥维生制药”）to apply the same closed-loop engineering approach to internally originated therapeutic programs. Matwings develops the underlying AI and protein-engineering technology engine, while Biowings Therapeutics combines these capabilities with disease biology and drug-development expertise to create and advance therapeutic candidates.. 将同样的闭环工程方法应用于内部发起的治疗项目。Matwings 开发底层的 AI 和蛋白质工程技术引擎，而 Biowings Therapeutics 则将这些能力与疾病生物学及药物开发专业知识相结合，以创建并推进候选治疗药物。'The real test of AI for science is not whether a model performs well on a benchmark, but whether it can create measurable value through repeated design–experiment cycles in an actual R&D program,' said Prof. Liang Hong, Founder and Chief Scientist of Matwings. “人工智能在科学领域的真正考验，不在于模型在基准测试中表现如何，而在于它能否在实际的研发项目中，通过反复的设计—实验循环创造可衡量的价值。”物质之翼创始人兼首席科学家梁宏教授表示。'GenSci148 marks an important step from demonstrating individual model capabilities toward building a repeatable protein-engineering system.' “GenSci148 标志着从展示单个模型能力向构建可重复的蛋白质工程系统迈出的重要一步。”'Matwings contributed important molecular engineering and optimization capabilities to the GenSci148 program,' said Dr. Lei Jin, CEO of GenSci. “Matwings为GenSci148项目贡献了重要的分子工程与优化能力。”GenSci首席执行官金磊博士表示。'Rather than relying on one-time predictions, the teams repeatedly combined AI-guided design with experimental evidence to improve properties relevant to drug development.' “各团队并未依赖一次性预测，而是反复将人工智能引导的设计与实验证据相结合，以改善与药物开发相关的特性。”About Matwings 关于MatwingsShanghai Matwings Technology Co., Ltd. 上海迈特温斯科技有限公司is an AI-driven protein R&D company integrating specialist AI models, computational molecular design and experimental validation to support iterative protein engineering and drug development. 是一家由人工智能驱动的蛋白质研发公司，整合专业AI模型、计算分子设计与实验验证，以支持迭代式蛋白质工程和药物开发。For more information, visit 更多信息，请访问www.matwings.com www.matwings.com. 。About Biowings Therapeutics 关于Biowings TherapeuticsShanghai Biowings Therapeutics Co., Ltd. 上海生物翼制药有限公司focuses on AI-enabled therapeutic asset creation and clinical translation. 专注于人工智能赋能的治疗性资产开发与临床转化。Scientific and Development Notice: 科学与开发通知：GenSci148 is an investigational product. Its safety and efficacy have not been established. Preclinical findings are specific to the experimental systems and conditions evaluated and may not predict clinical outcomes. GenSci148 是一种研究性产品。其安全性和有效性尚未确立。临床前研究结果特定于所评估的实验系统和条件，可能无法预测临床结局。Contact: 联系方式：Website: 网站：www.matwings.com www.matwings.comE-mail: 电子邮件：[emailprotected] [email protected]SOURCE Shanghai Matwings Technology Co., Ltd.; Shanghai Biowings Therapeutics Co., Ltd. 来源：上海迈威生物科技有限公司；上海百奥维治疗有限公司21 二十一% 百分比more press release views with 更多新闻稿浏览量与Request a Demo 申请演示

药械追踪 No.1 / 来凯医药/齐鲁制药AKT抑制剂阿氟色替在华申报上市 2026年8月12日，来凯医药（2105.HK）宣布，LAE002（盐酸阿氟色替片）的新药上市申请（NDA）已获中国国家药品监督管理局（NMPA）药品审评中心（CDE）受理，拟用于既往接受内分泌治疗（联合或不联合CDK4/6抑制剂）后出现疾病复发或进展、伴有任何PIK3CA/AKT1/PTEN基因改变的HR+/HER2-局部晚期或转移性乳腺癌患者。 阿氟色替是一种强效AKT抑制剂，能够同时抑制所有三种AKT亚型（AKT1、AKT2及AKT3）。其III期临床试验（AFFIRM-205）已达到无进展生存期（PFS）的主要终点，在HR+/HER2-乳腺癌患者中显示出统计学显著且具有临床意义的获益。 2025年11月，来凯医药与齐鲁制药签订独家许可协议，将阿氟色替的中国权益授予齐鲁制药。根据协议，来凯医药有资格获得总额最高达人民币20.45亿元的首付款及里程碑款项，同时有权就授权区域内的未来净销售额收取梯度销售分成，分成比例在十多个百分点至二十多个百分点之间。来凯医药计划在中国以外地区寻求战略合作伙伴，以加速阿氟色替在国际市场的开发及商业化进程。 ->点击文末阅读原文，解锁完整双语新闻 No.2 / 万泰生物九价HPV疫苗在泰国获批上市 2026年8月12日，万泰生物（603392.SH）发布公告称，公司自主研发的九价人乳头瘤病毒疫苗（大肠埃希菌）获得泰国食品药品监督管理局批准上市。 该疫苗是我国首款、全球第二款九价HPV疫苗，主要适用于9-45岁女性，覆盖HPV16/18/31/33/45/52/58七种高危型和HPV6/11两种低危型，可预防上述型别人乳头瘤病毒感染引起的相关疾病。 ->点击文末阅读原文，解锁完整双语新闻 No.3 / 昊海生物人工晶状体在华获批医疗器械注册证 2026年8月7日，昊海生物（6826.HK/688366.SH）发布公告称，公司三焦点环曲面人工晶状体获国家药监局批准上市，用于成人白内障合并角膜散光患者无晶体眼的视力矫正，以期待在矫正角膜散光的同时改善近、中、远视力并减少眼镜依赖。 本品通过国家创新医疗器械特别审批程序，成为国内首款获批上市的国产三焦点散光人工晶状体。该产品创新性地融合三焦点衍射光学设计与环曲面散光矫正技术，在改善白内障患者远、中、近视力的同时，有效矫正角膜散光，为伴有角膜散光的患者提供了更为完善的全程视力解决方案。 ->点击文末阅读原文，解锁完整双语新闻 企业动态 No.1 /迈威生物就阿柏西普生物类似药在多个东盟国家达成战略合作 2026年8月12日，迈威生物（688062.SH/2493.HK）宣布，就 9MW0813（阿柏西普眼内注射溶液）在菲律宾、越南、马来西亚分别与当地合作方达成许可协议。根据协议，迈威生物将与合作方共同推进产品在当地的注册和商业化。 阿柏西普由拜耳原研（商品名：艾力雅/EYLEA），是新生血管（湿性）年龄相关性黄斑变性（nAMD）和糖尿病性黄斑水肿（DME）等多种眼底疾病的一线用药。作为一种人源化融合蛋白，阿柏西普能够与血管内皮生长因子（VEGF-A、VEGF-B）及胎盘生长因子（PlGF）结合，相比抗VEGF单抗类药物作用靶点更广泛。迈威生物9MW0813是参照艾力雅研制的阿柏西普生物类似药。 ->点击文末阅读原文，解锁完整双语新闻 全球医疗情报领导者 解锁隐藏在数据中的商业潜力  关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。 联系我们 投稿 | 发稿 | 媒体合作 ▶ olivia.xu@generalbiologic.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写 点击阅读原文，解锁完整双语新闻